Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma-Reference-Cited by-同舟云学术

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma

Published:2020-09-18 Issue:1 Volume:193 Page:160-170
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Mithraprabhu Sridurga¹²^ORCID,Kalff Anna¹²,Gartlan Kate H.³,Savvidou Ioanna¹²^ORCID,Khong Tiffany¹²,Ramachandran Malarmathy¹²,Cooke Rachel E.²⁴,Bowen Kathryn²,Hill Geoffrey R.⁵,Reynolds John⁶,Spencer Andrew¹²⁷

Affiliation:

1. Myeloma Research Group Australian Centre for Blood DiseasesAlfred Hospital‐Monash University MelbourneVictoriaAustralia

2. Malignant Haematology and Stem Cell Transplantation Alfred Hospital Melbourne VictoriaAustralia

3. QIMR Berghofer Medical Research Institute Herston QueenslandAustralia

4. Haematology Department Northern Health Melbourne Victoria Australia

5. Clinical Research Division Fred Hutchinson Cancer Research Centre Seattle, Washington United States

6. Epidemiology and Preventive Medicine Alfred Health – Monash University MelbourneVictoriaAustralia

7. Department of Clinical Haematology Monash University Clayton Victoria Australia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17080

Reference51 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

2. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

3. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

4. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

5. Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial;Jackson G;Blood,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells;Oncotarget;2024-03-05

2. Treatment of multiple myeloma: What is the impact on T-cell function?;Therapeutic Advances in Hematology;2024-01

3. Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response;Cancers;2023-08-07

4. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2021-11

5. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention;Blood Advances;2021-07-09